161. Karger Publishers A journal of pharmacological and biophysical research. Sample issue available online. http://www.karger.com/journals/sph/sph_jh.htm

Journal Home Editorial Board Guidelines Issues ... Online Sample Editor(s): Lademann, J. (Berlin) Current Issue Top 5 articles An innovative approach to recent developments Published online first All articles are published electronically ahead of print with the definite citation line. Thus, an article will be available online shortly after the author's approval to print. Aims and Scope In the past decade research into skin pharmacology has developed dramatically with new and promising drugs and therapeutic concepts being introduced regularly. Recent examples include immunosuppressive topicals, and new strategies in the therapy of malignant melanoma and wound healing. New concepts have also been developed in traditional areas of skin therapy and skin care which have led to discussions of issues such as ‘cosmeceuticals’ in the United States, ‘quasi-drugs’ in Japan, and the 6th Amendment of the Cosmetic Regulation in the European Union. There are many open questions which reflect the importance of the subject and the need for a new international scientific forum where they can be discussed in extenso. Dermatologists, pharmaceutical chemists, pharmacologists, toxicologists, and others interested in the subject are invited to contribute to this exciting project and to submit their best research work for publication. Journal of the International Society of Skin Pharmacology and Physiology Skin Pharmacology and Physiology www.karger.com/spp

162. Cerep Provides Services In Pharmacology, Biology, And Chemistry Provides services in pharmacology, in molecular biology and lead development, in toxicology, metabolism and bioavailability, in combinatorial chemistry, HTS, HTP, HTLD and computational chemistry. http://www.cerep.fr/

Cerep provides services in pharmacology, in molecular biology and lead development, in toxicology, metabolism and bio-availability, in combinatorial and computational chemistry, HTS, HTP, HTLD. cerep is recognized as the partner of choice for drug discovery and development by pharmaceutical and biotech companies throughout the world. Through its laboratory located near Poitiers (France), Cerep provides services in molecular and cellular pharmacology. Additional services in molecular biology and pharmaceutical profiling are now available from its state-of-the art laboratory in Redmond (Washington, USA). cerep provides scientific studies developed and tailored to the requirements of the Industry. The purpose of these studies is to contribute to the selection and development of new molecules or to the evaluation of existing drugs. BioPrint™ is a powerful tool for drug discovery. BioPrint™ consists of a proprietary database, predictive models and software tools for data visualization, analysis and searching. The BioPrint™ Database is used to generate predictive models based on correlations between molecular features and patterns of biological activity.

163. Oxycodone ( Percodan , Percocet , Roxicodone, Oxycontin, Oxyfast ) Explores various issues regarding the pharmacology, uses, and problems associated with this narcotic. http://opioids.com/oxycodone/index.html

Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation by Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG Arthritis Center Ltd, Phoenix, Ariz, USA. Arch Intern Med 2000 Mar 27;160(6):853-60 ABSTRACT B ACKGROUND: Although opioid analgesics have well-defined efficacy and safety in treatment of chronic cancer pain, further research is needed to define their role in treatment of chronic noncancer pain. OBJECTIVE: To evaluate the effects of controlled-release oxycodone (OxyContin tablets) treatment on pain and function and its safety vs placebo and in long-term use in patients with moderate to severe osteoarthritis pain. METHODS: One hundred thirty-three patients experiencing persistent osteoarthritis-related pain for at least 1 month were randomized to double-blind treatment with placebo (n = 45) or 10 mg (n = 44) or 20 mg (n = 44) of controlled-release oxycodone every 12 hours for 14 days. One hundred six patients enrolled in an open-label, 6-month extension trial; treatment for an additional 12 months was optional. RESULTS: Use of controlled-release oxycodone, 20 mg, was superior (P <.05) to placebo in reducing pain intensity and the interference of pain with mood, sleep, and enjoyment of life. During long-term treatment, the mean dose remained stable at approximately 40 mg/d after titration, and pain intensity was stable. Fifty-eight patients completed 6 months of treatment, 41 completed 12 months, and 15 completed 18 months. Common opioid side effects were reported, several of which decreased in duration as therapy continued. CONCLUSIONS: Around-the-clock controlled-release oxycodone therapy seemed to be effective and safe for patients with chronic, moderate to severe, osteo-arthritis-related pain. Effective analgesia was accompanied by a reduction in the interference of pain with mood, sleep, and enjoyment of life. Analgesia was maintained during long-term treatment, and the daily dose remained stable after titration. Typical opioid side effects were reported during short- and long-term therapy.

164. Journal Of Cardiovascular Pharmacology - Home Reports on advances in cardiovascular drug research and use. Table of contents, author guidelines, editorial board and subscription information. http://www.cardiovascularpharm.com

LWWOnline LOGIN eALERTS REGISTER ... ePrints/Reprints SUBSCRIPTION SERVICES New Subscriptions Renewal Information Trial Issue Request Special Sales Important Message: Easily submit and review manuscripts online with LWW's Prompt/Editorial Manager . This automated, web-based tool simplifies the manuscript submission and review processes and enables users to electronically submit, review and track manuscripts and artwork online in a few easy steps. We invite contributors and reviewers to begin using the Prompt/Editorial Manager interface today at http://jcvp.edmgr.com is the leading journal devoted exclusively to reports on important advances in cardiovascular drug research and use. Each monthly issue provides the most current information on physiological and pharmacological bases of drug action, metabolism, drug interaction, side effects, and clinical results with both new and established drugs. ISSN: Online ISSN: Frequency: Twelve issues per year Editor Paul M Vanhoutte MD, PhD Michael R Rosen MD Original articles covering new basic and clinical research Reports on advances in cardiovascular drug research and use ET-8: Eighth International Conference on Endothelin Clinical Trials.gov:

165. MDS Pharma Services Provides pharmacology, lead discovery, HTS, metabolism, drug discovery, drug development, safety pharmacology, biotechnology, and biosafety contract research services. http://www.mdsps.com/

Locations Study Participation Investigators Career ... Global Clinical Development Central Lab Integrated Cardiovascular Safety Assessment Scientific Expertise and Resources Cardiovascular Safety Testing Centralized ECG Services ECG Locations ECG Devices Regulatory Guidelines ... Global Regulatory Affairs EU Clinical Trials Directive MDS Pharma Services introduces its platform of integrated Cardiovascular Safety Assessment services. Our leading digital ECG solutions have been bolstered by the integration of complete capabilities from in vitro pharmacology through late-stage clinical services. With MDS Pharma Services, your success is always top of mind. Knowledge and resources to propel innovation and accelerate the drug development process. Therapeutic Monoclonal Antibody Smarter solutions all mapped out for you! Take a moment to explore our exclusive new guide for large molecule development. Science, Service and Solutions Whether you require a single-service component or an entire drug development program, we are ready to put our minds to work for you. Providing innovative solutions around the world.

166. Fastin Online, Description, Chemistry, Ingredients - Phentermine - RxList Monogr Provides drug clinical pharmacology, side effects, and patient information. http://www.rxlist.com/cgi/generic/phenterm.htm

document.writeln(''); document.writeln(''); Phentermine document.writeln(''); document.writeln(''); Company Issues Pacemaker Malfunction Warning Deaths Seen With Fentanyl Narcotic Pain Patch FDA Reviews Adult Antidepressant-Suicide Link DESCRIPTION Each phentermine hydrochloride capsule contains phentermine hydrochloride, 30 mg (equivalent to 24 mg Phentermine). Phentermine Hydrochloride is a white crystalline powder, very soluble in water and alcohol. Chemically, the product is phenyl-tertiary-butylamine hydrochloride. Inactive Ingredients: gelatin document.writeln(''); document.writeln(''); document.writeln(''); document.writeln(''); For information on ordering Fastin Online, please click the "online pharmacy" link on the blue horizontal navigation bar at the top of every page. This Page Last Updated 12/08/2004

167. Department Of Pharmacology And Toxicology Provides program and course outlines with student handbooks, including graduate programs. http://meds.queensu.ca/medicine/pharm/

Pharmacology and Toxicology at Queen's University The Department of Pharmacology and Toxicology began life in 1854 with the appointment of Materia Medica. The initial responsibility was primarily the education of medical students which was shouldered by a number of appointees until 1938 when Dr. Eldon Boyd was appointed Professor and Head of the Department of Pharmacology. With his appointment, the training of graduate students was initiated; some 26 theses were completed during the ensuing 30 years. With the appointment in 1969 of Dr. Gerald S. Marks, the department began a period of rejuvenation with the hiring of several new faculty members, a change in its research profile, and new forays in teaching with participation in the instruction of Arts and Science undergraduates through the nascent Life Sciences program in 1970. Prior to 1969, the teaching responsibilities were limited to 75 medical students and a handful of graduate students. From 1970 to 2000, 176 graduate students completed their theses. In 2003/2004, the department comprised ten faculty members, four and a half support staff, and 40 graduate students. The primary undergraduate teaching responsibilities were 80 medical students, 70 nursing students, and the rapidly growing Life Sciences program.

168. Paroxetine Canadian monograph, from Internet Mental Health, includes pharmacology, indications, contraindications, precautions, adverse effects, dosage and research. http://www.mentalhealth.com/drug/p30-p02.html

Paroxetine Brand name: Paxil Drug monograph Contents Summary Paxil CR Summary Paxil IR Pharmacology Indications ... Research Summary Paxil CR PAXIL CR GlaxoSmithKline Paroxetine HCI Use: SSRI. Symptomatic relief of depressive illness: Initially, usually in the morning, a 25 mg single daily dose. Patients unresponsive to a 25 mg dose may benefit from dose increases, in 12.5 mg/day increments, at intervals of at least 1 week, to a maximum of 62.5 mg/day. Symptomatic relief of panic disorder: Initially, usually in the morning, a 12.5 mg single daily dose. Dose changes at intervals of at least 1 week should occur in 12.5 mg/day increments. Maximum dosage: 75 mg/day. Social phobia (social anxiety disorder): Initially, usually in the morning, a 12.5 mg single daily dose. Patients unresponsive to a 12.5 mg dose may benefit from dose increases, in 12.5 mg/day increments, at intervals of at least 1 week, to a maximum of 37.5 mg/day. Tablets should be swallowed whole and not chewed or crushed. Contraindications: Not to be used with an MAOI or within 14 days of starting or discontinuing MAOI therapy. Concomitant administration of thioridazine. Contraindicated in patients

169. Iranian Journal Of Pharmacology & Therapeutics (IJPT Home Page) IJPT publishes quarterly regular research papers, reviews, minireviews and case reports which deal with all aspects of experimental and clinical pharmacology. http://ijpt.iums.ac.ir

ISSN 1735-2657 Call for Papers Aims and Scope Editors and Editorial Board Current Issue E-lert Service Feedback Positions Back Issues Whole web IJPT Razi Institute for Drug Research of IUMS ijpt@iums.ac.ir

170. Queen's University - Life Sciences Program Departments offering bachelors' degrees in anatomy and cell biology, biochemistry, microbiology and immunology, pathology, physiology, pharmacology and toxicology. http://meds.queensu.ca/lifesciences/lshomepg.htm

1997 marked the 25th anniversary of the Life Sciences program at Queen's University. The first graduating class in 1972 numbered two; twenty-five years and over 1,500 graduates later, the class of '96 numbered 150. In the 2003/04 academic year there are 1,094 undergraduate students enrolled in one of the B.Sc. programs with a Life Sciences concentration. B.Sc. General Concentration in Life Sciences/Diploma in Respiratory Therapy (Note: This program has been discontinued; information pertains to students already registered in it.) B.Sc. General Concentration in Life Sciences/Diploma in X-Ray Technology Life Sciences Research Day Research Project Guidelines Announcements ... On-line Resources for Students Life Sciences Program, Queen's University Botterell Hall, Room 224 Phone (613) 533-6527 FAX (613) 533-6925 Dr. William J. Racz, Associate Dean Ms. Katherine Rudder, Administrative Secretary Although care has been taken in preparing the information contained on this website, the Life Sciences Office and/or Queen's University does not and cannot guarantee the accuracy thereof. Anyone using the information does so at their own risk and shall be deemed to indemnify Queen's University from any and all injury or damage arising from such use. No central authority. Since this is a distributed system, the pages you reach from our "official" pages are maintained by many people at other sites, who have individual control over the content of their pages.

171. Loxapine Internet Mental Health page discusses pharmacology, indications and contraindications, precautions, dosage, and other topics. From a Canadian monograph. http://www.mentalhealth.com/drug/p30-l03.html

Loxapine Brand names: Loxapac, Loxitane Drug monograph Contents Pharmacology Indications Contraindications Warnings ... Research Pharmacology Antipsychotic Agent Loxapine, a tricyclic dibenzoxazepine antipsychotic agent, which is chemically distinct from the phenothiazines, thioxanthenes and butyrophenones, produces pharmacological responses in various animal species which are characteristic of those seen with the majority of antipsychotic drugs. Although the precise mechanism of action is not known, loxapine succinate administration results in strong inhibition of spontaneous motor activity. Absorption following orally administered loxapine succinate is virtually complete. Following oral administration of a single 25 mg dose of loxapine, the onset of sedative effect occurs in 15 to 30 minutes; peak effect occurs within 1.0 to 3 hours. The duration of sedative effect is approximately 12 hours. Loxapine is metabolized rapidly and extensively in animals and man and excreted both in the urine and feces. There appear to be 3 reactions, other than phenol conjugation, involved in the metabolism of loxapine: aromatic hydroxylation, N-oxidation and N-demethylation. Unmetabolized drug has not been recovered in urine and feces though metabolites are excreted in urine mainly in the form of conjugates and in feces mainly in the unconjugated form. In rats, 86 to 96% of orally administered doses of loxapine has been recovered in urine and feces. In dogs, 92 to 104% has been similarly recovered. Approximately 50% of the drug is recovered within the first 24 hours.

172. Clinical Neuropharmacology - Home Bimonthly journal devoted to the pharmacology of the nervous system. Contents, author guidelines, editorial board and subscription information. http://www.clinicalneuropharm.com

LWWOnline LOGIN eALERTS REGISTER ... ePrints/Reprints SUBSCRIPTION SERVICES New Subscriptions Renewal Information Trial Issue Request Special Sales Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers. Important Message: Easily submit and review manuscripts online with LWW's Prompt/Editorial Manager . This automated, web-based tool simplifies the manuscript submission and review processes and enables users to electronically submit, review and track manuscripts and artwork online in a few easy steps. We invite contributors and reviewers to begin using the Prompt/Editorial Manager interface today at http://cnp.edmgr.com

173. Hong Kong Pharmacology Society The main objective of the society is to promote interest in both basic and clinical pharmacology. http://www.fmshk.com.hk/hkpharmacology/

174. Astrolathe http://www.pharmcentral.com/

This page uses frames, but your browser doesn't support them.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 9     161-174 of 174    Back | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9